GlaxoSmithKline Pharmaceuticals Limited

NSEI:GLAXO Voorraadrapport

Marktkapitalisatie: ₹409.1b

GlaxoSmithKline Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Bhushan Akshikar

Algemeen directeur

₹66.9m

Totale compensatie

Percentage CEO-salaris21.7%
Dienstverband CEO1.9yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijn2.1yrs
Gemiddelde ambtstermijn bestuur6.6yrs

Recente managementupdates

Recent updates

GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Nov 01
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease

Aug 29
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease

The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 05
The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%

Jun 01
Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%

With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case

May 05
With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case

GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear

Apr 14
GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear

Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 15
Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?

Jan 18
Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?

GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected

Dec 28
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected

Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today

Oct 05
Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?

Sep 12
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet

Mar 17
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet

Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?

Sep 02
Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly

Mar 02
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly

The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

Mar 20
The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Feb 27
Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?

Feb 06
Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?

What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?

Jan 11
What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain

Dec 06
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain

Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts

Nov 01
Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts

Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield

Oct 29
Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield

What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?

Sep 29
What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?

If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today

Aug 30
If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today

Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?

Aug 02
Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?

It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend

Jul 12
It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend

Analyse CEO-vergoeding

Hoe is Bhushan Akshikar's beloning veranderd ten opzichte van GlaxoSmithKline Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

₹7b

Jun 30 2024n/an/a

₹6b

Mar 31 2024₹67m₹15m

₹6b

Dec 31 2023n/an/a

₹5b

Sep 30 2023n/an/a

₹6b

Jun 30 2023n/an/a

₹6b

Mar 31 2023₹34m₹4m

₹6b

Compensatie versus markt: De totale vergoeding ($USD 792.12K ) Bhushan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 779.51K ).

Compensatie versus inkomsten: De vergoeding van Bhushan is het afgelopen jaar met meer dan 20% gestegen.


CEO

Bhushan Akshikar

1.9yrs

Tenure

₹66,885,000

Compensatie

Mr. Bhushan Akshikar is Managing Director of GlaxoSmithKline Pharmaceuticals Limited from December 1, 2022. He served as Additional Director of GlaxoSmithKline Pharmaceuticals Limited since March 18, 2021...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Bhushan Akshikar
MD & Executive Director1.9yrs₹66.89mgeen gegevens
Juby Chandy
Whole-Time Director & CFO2.6yrs₹68.92mgeen gegevens
Chinmay Sharma
Executive Vice President of Human Resources3.9yrs₹37.40mgeen gegevens
Aparajita Rajput
Vice President of Technologyless than a yeargeen gegevensgeen gegevens
Ajay Nadkarni
VP of Administration & Real Estate and Company Secretaryno data₹11.57mgeen gegevens
Amit Pandey
Executive Vice President of Legal2.8yrsgeen gegevensgeen gegevens
Simrat Sohal
Vice President of Ethics & Compliance1.8yrsgeen gegevensgeen gegevens
Ransom D'Souza
Executive Vice President of Communications & Government Affairs7.6yrsgeen gegevensgeen gegevens
Sukanya Choudhary
Executive Vice-President of Regulatory Affairsno datageen gegevensgeen gegevens
Shourov Mukherjee
Executive Vice-President of Adult Vaccines2.3yrsgeen gegevensgeen gegevens
Upendra Singh
Executive Vice President of General Medicines1.9yrsgeen gegevensgeen gegevens
Sharmishta Mitra
Commercial Head - Paediatric Vaccines1.8yrsgeen gegevensgeen gegevens

2.1yrs

Gemiddelde duur

Ervaren management: Het managementteam van GLAXO wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Bhushan Akshikar
MD & Executive Directorno data₹66.89mgeen gegevens
Juby Chandy
Whole-Time Director & CFO2.6yrs₹68.92mgeen gegevens
Renu Karnad
Non-Executive Chairperson5.6yrs₹3.25mgeen gegevens
Manu Anand
Independent Director2.5yrs₹2.65mgeen gegevens
Damodarannair Sundaram
Non-Executive Independent Director15.3yrs₹2.70mgeen gegevens
Subesh Williams
Non Executive Director7.6yrsgeen gegevensgeen gegevens
Pradeep Bhide
Non-Executive Independent Director14.1yrs₹2.70mgeen gegevens
Anami Narayan Roy
Non-Executive Independent Director13yrs₹2.45mgeen gegevens
Sunita Maheshwari
Non-Executive & Independent Director4.5yrs₹2.45mgeen gegevens

6.6yrs

Gemiddelde duur

68.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GLAXO wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.6 jaar).